Alzheon, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-06-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alzheon.com
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Phase 3
Active, not recruiting
- Conditions
- Early Alzheimer's Disease
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT06304883
- Locations
- 🇬🇧
NeuroClin Glasgow Ltd, Motherwell, North Lanarkshire, United Kingdom
🇺🇸Abington Neurological Associates, Abington, Pennsylvania, United States
🇺🇸Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Phase 3
Completed
- Conditions
- Early Alzheimer's Disease
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT04770220
- Locations
- 🇳🇱
Brain Research Center Zwolle, Zwolle, Netherlands
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
🇪🇸Hospital Clinico San Carlos, Madrid, Spain
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04693520
- Locations
- 🇳🇱
Brain Research Center, Zwolle, Netherlands
🇨🇿Vestra Clinics, Rychnov Nad Kněžnou, Czechia
🇨🇿St. Anne's University Hospital, Brno, Czechia
Single Dose Study of ALZ-801 Prototype Tablets
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: ALZ-801 205 mg After FoodDrug: ALZ-801 170 mg FastingDrug: ALZ-801 205 mg FastingDrug: ALZ-801 342 mg Fasting
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04585347
Multiple Ascending Dose Study of ALZ-801
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: ALZ-801 or matching placebo
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04157712
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath